This lecture was given by Professor Daniel Gaudet, MD, Ph.D. at the 90th EAS Congress in Milan Italy, in 2022.
Professor Gaudet is the founder and director of the ECOGENE-21 Clinical Research Center in the Department of Medicine, University of Montreal, Canada.
In his excellent lecture, Professor Gaudet presented new data on the effect of a human monoclonal antibody against the angiopoietin-like 3/8 (ANGPTL3/8) complex in subjects with mixed hyperlipidemia.
He started his lecture by discussing the role of ANGPTL3/8 in the lipoprotein lipase (LPL) – Triglyceride (TG)-rich lipoproteins machinery and presented data on the effect of loss-of-function (LOF) mutations and pharmacological inhibition of ANGPTL3 on TG, low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) levels.
Subsequently, he presented the design and results of a randomized, double-blind, placebo-controlled study involving 48 subjects with mixed hyperlipidemia (TG levels ≥1.5mmol/L [≥135mg/dL] and LDL-C ≥1.8mmol/L [≥70mg/dL]) who received a single ascending dose of a monoclonal antibody against the ANGPTL3/8 complex, LY3475766 for 28 days, He showed that a single dose of LY3475766 significantly reduced TG and remnant cholesterol levels as well as LDL-C, non-HDL-C, and apolipoprotein B levels and increased HDL-C levels. There were no serious adverse events. He concluded that inhibition of ANGPTL3/8 complex with LY3475766 may have the potential to reduce cardiovascular risk in these patients when administered on top of optimal standard of care treatment.